TABLE OF CONTENTS
1 INTRODUCTION 53
1.1 OBJECTIVES OF THE STUDY 53
1.2 MARKET DEFINITION 53
1.3 OVERVIEW OF MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 53
1.4 LIMITATIONS 55
1.5 MARKETS COVERED 56
2 MARKET SEGMENTATION 59
2.1 MARKETS COVERED 59
2.2 GEOGRAPHICAL SCOPE 60
2.3 YEARS CONSIDERED FOR THE STUDY 61
2.4 CURRENCY AND PRICING 61
2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
2.6 MULTIVARIATE MODELLING 65
2.7 PRODUCT TYPE LIFELINE CURVE 65
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.9 DBMR MARKET POSITION GRID 67
2.10 MARKET END USER COVERAGE GRID 69
2.11 VENDOR SHARE ANALYSIS 70
2.12 SECONDARY SOURCES 71
2.13 ASSUMPTIONS 71
3 EXECUTIVE SUMMARY 72
4 PREMIUM INSIGHTS 75
4.1 PESTEL ANALYSIS 76
4.2 PORTER'S 5 FORCES 77
5 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 78
5.1 REGULATORY SCENARIO IN THE U.S. 78
5.2 REGULATORY SCENARIO IN AUSTRALIA 79
5.3 REGULATORY SCENARIO IN JAPAN 79
5.4 REGULATORY SCENARIO IN CHINA 79
6 MARKET OVERVIEW 81
6.1 DRIVERS 83
6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 83
6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 85
6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 85
6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 86
6.2 RESTRAINTS 87
6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 87
6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 87
6.3 OPPORTUNITIES 88
6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 88
6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 88
6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 89
6.4 CHALLENGES 90
6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 90
6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 90
7 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 91
7.1 OVERVIEW 92
7.2 INSTRUMENTS 95
7.2.1 BIOPSY INSTRUMENTS 96
7.2.1.1 BONE MARROW BIOPSY 96
7.2.1.2 NEEDLE BIOPSY 96
7.2.1.3 SURGICAL BIOPSY 96
7.2.1.4 OTHERS 97
7.2.2 PATHOLOGY-BASED INSTRUMENTS 97
7.2.2.1 PCR INSTRUMENTS 97
7.2.2.2 SLIDE STAINING SYSTEMS 97
7.2.2.3 TISSUE PROCESSING SYSTEMS 97
7.2.2.4 CELL PROCESSORS 97
7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 98
7.2.3 IMAGING INSTRUMENTS 98
7.2.3.1 ULTRASOUND SYSTEMS 98
7.2.3.2 CT SYSTEMS 98
7.2.3.3 MRI SYSTEMS 98
7.2.3.4 OTHERS 98
7.2.4 OTHERS 98
7.3 CONSUMABLES & ACCESSORIES 99
7.3.1 KITS 100
7.3.1.1 PCR KITS 100
7.3.1.2 DNA POLYMERASE KITS 100
7.3.1.3 NUCLEIC ACID ISOLATION KITS 100
7.3.1.4 OTHERS 101
7.3.2 REAGENTS 101
7.3.2.1 ASSAYS 101
7.3.2.2 BUFFERS 101
7.3.2.3 PRIMERS 101
7.3.2.4 OTHERS 101
7.3.3 PROBES 102
7.3.4 OTHER CONSUMABLES 102
8 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 103
8.1 OVERVIEW 104
8.2 BLOOD TEST 107
8.2.1 COMPLETE BLOOD COUNT (CBC) 108
8.2.2 BLOOD CHEMISTRY TESTS 108
8.2.3 OTHERS 108
8.3 IMAGING TEST 108
8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 109
8.3.2 MRI 109
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 110
8.3.4 OTHERS 110
8.4 BONE MARROW TESTS 110
8.4.1 BONE MARROW ASPIRATE 111
8.4.2 BONE MARROW BIOPSY 111
8.4.3 OTHERS 111
8.5 GENETIC TESTS 111
8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 112
8.5.2 KARYOTYPING 112
8.5.3 OTHERS 112
8.6 BIOMARKER TEST 112
8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113
8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113
8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 114
8.7 IMMUNOPHENOTYPING 114
8.7.1 FLOW CYTOMETRY 115
8.7.2 IMMUNOHISTOCHEMISTRY 115
8.7.3 OTHERS 115
8.8 OTHERS 115
9 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 117
9.1 OVERVIEW 118
9.2 MYELOBLASTIC (M0) 121
9.3 MYELOBLASTIC (M1) 121
9.4 MYELOBLASTIC (M2) 122
9.5 PROMYELOCYTIC (M3) 123
9.6 MYELOMONOCYTIC (M4) 124
9.7 MONOCYTIC (M5) 124
9.8 ERYTHROLEUKEMIA (M6) 125
9.9 MEGAKARYOCYTIC (M7) 126
10 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 127
10.1 OVERVIEW 128
10.2 65 AND ABOVE 131
10.3 30-65 131
10.4 BELOW 21 132
10.5 21-29 133
11 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 135
11.1 OVERVIEW 136
11.2 MALE 139
11.3 FEMALE 139
12 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 141
12.1 OVERVIEW 142
12.2 HOSPITALS 145
12.3 ASSOCIATED LABS 145
12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 146
12.5 DIAGNOSTIC IMAGING CENTERS 147
12.6 CANCER RESEARCH INSTITUTES 147
12.7 OTHERS 148
13 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 150
13.1 OVERVIEW 151
13.2 DIRECT TENDER 154
13.3 RETAIL SALES 154
14 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 156
14.1 MIDDLE EAST AND AFRICA 157
14.1.1 SOUTH AFRICA 169
14.1.2 SAUDI ARABIA 175
14.1.3 UAE 181
14.1.4 EGYPT 187
14.1.5 ISRAEL 193
14.1.6 REST OF MIDDLE EAST AND AFRICA 199
15 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 200
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 200
16 SWOT ANALYSIS 201
17 COMPANY PROFILE 202
17.1 CANON MEDICAL SYSTEMS CORPORATION. 202
17.1.1 COMPANY SNAPSHOT 202
17.1.2 REVENUE ANALYSIS 202
17.1.3 COMPANY SHARE ANALYSIS 203
17.1.4 PRODUCT PORTFOLIO 203
17.1.5 RECENT DEVELOPMENT 203
17.2 SYSMEX CORPORATION 204
17.2.1 COMPANY SNAPSHOT 204
17.2.2 REVENUE ANALYSIS 204
17.2.3 COMPANY SHARE ANALYSIS 205
17.2.4 PRODUCT PORTFOLIO 205
17.2.5 RECENT DEVELOPMENT 205
17.3 EPIGENOMICS AG. 206
17.3.1 COMPANY SNAPSHOT 206
17.3.2 REVENUE ANALYSIS 206
17.3.3 COMPANY SHARE ANALYSIS 207
17.3.4 PRODUCT PORTFOLIO 207
17.3.5 RECENT DEVELOPMENT 207
17.4 MYRIAD GENETICS, INC.. 208
17.4.1 COMPANY SNAPSHOT 208
17.4.2 REVENUE ANALYSIS 208
17.4.3 COMPANY SHARE ANALYSIS 209
17.4.4 PRODUCT PORTFOLIO 209
17.4.5 RECENT DEVELOPMENT 209
17.5 F. HOFFMANN- LA ROCHE LTD 210
17.5.1 COMPANY SNAPSHOT 210
17.5.2 REVENUE ANALYSIS 210
17.5.3 COMPANY SHARE ANALYSIS 211
17.5.4 PRODUCT PORTFOLIO 211
17.5.5 RECENT DEVELOPMENT 211
17.6 ABBOTT 212
17.6.1 COMPANY SNAPSHOT 212
17.6.2 REVENUE ANALYSIS 212
17.6.3 PRODUCT PORTFOLIO 213
17.6.4 RECENT DEVELOPMENT 213
17.7 AGILENT TECHNOLOGIES, INC. 214
17.7.1 COMPANY SNAPSHOT 214
17.7.2 REVENUE ANALYSIS 214
17.7.3 PRODUCT PORTFOLIO 215
17.7.4 RECENT DEVELOPMENT 215
17.8 BD 216
17.8.1 COMPANY SNAPSHOT 216
17.8.2 REVENUE ANALYSIS 216
17.8.3 PRODUCT PORTFOLIO 217
17.8.4 RECENT DEVELOPMENT 217
17.9 BIOMERIEUX 218
17.9.1 COMPANY SNAPSHOT 218
17.9.2 PRODUCT PORTFOLIO 218
17.9.3 RECENT DEVELOPMENT 218
17.10 BIO-RAD LABORATORIES, INC. 219
17.10.1 COMPANY SNAPSHOT 219
17.10.2 REVENUE ANALYSIS 219
17.10.3 PRODUCT PORTFOLIO 220
17.10.4 RECENT DEVELOPMENT 220
17.11 DIASORIN S.P.A. 221
17.11.1 COMPANY SNAPSHOT 221
17.11.2 REVENUE ANALYSIS 221
17.11.3 PRODUCT PORTFOLIO 222
17.11.4 RECENT DEVELOPMENTS 222
17.12 EXACT SCIENCES CORPORATION 223
17.12.1 COMPANY SNAPSHOT 223
17.12.2 REVENUE ANALYSIS 223
17.12.3 PRODUCT PORTFOLIO 224
17.12.4 RECENT DEVELOPMENTS 224
17.13 FONAR CORP. 225
17.13.1 COMPANY SNAPSHOT 225
17.13.2 REVENUE ANALYSIS 225
17.13.3 PRODUCT PORTFOLIO 226
17.13.4 RECENT DEVELOPMENT 226
17.14 HOLOGIC INC. 227
17.14.1 COMPANY SNAPSHOT 227
17.14.2 REVENUE ANALYSIS 227
17.14.3 PRODUCT PORTFOLIO 228
17.14.4 RECENT DEVELOPMENT 228
17.15 ILLUMINA, INC. 229
17.15.1 COMPANY SNAPSHOT 229
17.15.2 REVENUE ANALYSIS 229
17.15.3 PRODUCT PORTFOLIO 230
17.15.4 RECENT DEVELOPMENT 230
17.16 KONINKLIJKE PHILIPS N.V. 231
17.16.1 COMPANY SNAPSHOT 231
17.16.2 REVENUE ANALYSIS 231
17.16.3 PRODUCT PORTFOLIO 232
17.16.4 RECENT DEVELOPMENT 232
17.17 MEDONICA CO. LTD 233
17.17.1 COMPANY SNAPSHOT 233
17.17.2 PRODUCT PORTFOLIO 233
17.17.3 RECENT DEVELOPMENT 233
17.18 MERCK KGAA 234
17.18.1 COMPANY SNAPSHOT 234
17.18.2 REVENUE ANALYSIS 234
17.18.3 PRODUCT PORTFOLIO 235
17.18.4 RECENT DEVELOPMENTS 235
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD 236
17.19.1 COMPANY SNAPSHOT 236
17.19.2 PRODUCT PORTFOLIO 236
17.19.3 RECENT DEVELOPMENT 236
17.20 PLEXBIO 237
17.20.1 COMPANY SNAPSHOT 237
17.20.2 PRODUCT PORTFOLIO 237
17.20.3 RECENT DEVELOPMENTS 237

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.